DVA
DAVITA INC.
NYSE · Healthcare · Medical - Care Facilities · US
$189.36
+3.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 14.2B | 13.6B | 12.8B | 12.1B | 11.6B |
| Cost of Revenue | 9.8B | 10.0B | 8.6B | 8.3B | 8.2B |
| Gross Profit | 4.4B | 3.7B | 4.2B | 3.8B | 3.4B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 1.7B | 1.7B | 1.5B | 1.5B | 1.4B |
| General & Admin Expense | 1.7B | 1.7B | 1.5B | 1.5B | 1.4B |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 556.4M | — | 588.2M | 743.7M | 706.1M |
| Total Operating Expenses | 2.3B | 1.7B | 2.1B | 2.2B | 2.1B |
| Cost and Expenses | 12.1B | 11.6B | 10.7B | 10.5B | 10.3B |
| Operating Income (EBIT) | 2.1B | 2.0B | 2.1B | 1.6B | 1.3B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 559.6M | 549.7M | 470.5M | 398.6M | 357.0M |
| Net Interest Income | (559.6M) | (549.7M) | (470.5M) | (398.6M) | (357.0M) |
| Other Non-Op Income/Expense | (585.5M) | (663.8M) | (560.1M) | (425.7M) | (372.8M) |
| Non-Operating Income (excl Interest) | 750.0K | 83.9M | 89.6M | 27.1M | 15.8M |
| EBT (Pre-Tax Income) | 1.5B | 1.3B | 1.5B | 1.2B | 966.3M |
| Income Tax Expense | 324.0M | 293.1M | 279.7M | 220.1M | 198.1M |
| Bottom Line | |||||
| Net Income | 920.1M | 746.8M | 936.3M | 691.5M | 560.4M |
| Earnings from Cont. Ops | 1.2B | 1.1B | 1.3B | 957.0M | 768.2M |
| Earnings from Discont. Ops | 25.0M | 25.0M | — | — | 13.5M |
| Bottom Line Net Income | 895.1M | 721.8M | 936.3M | 691.5M | 560.4M |
| Per Share | |||||
| Basic EPS | $13.03 | $9.72 | $11.02 | $7.62 | $5.88 |
| Diluted EPS | $12.74 | $9.51 | $10.73 | $7.42 | $5.71 |
| Revenue Per Share | $221.94 | $158.46 | $150.79 | $133.72 | $124.85 |
| Shares | |||||
| Basic Shares Outstanding | 63.8M | 86.1M | 85.0M | 90.8M | 93.0M |
| Diluted Shares Outstanding | 65.5M | 88.1M | 87.3M | 93.2M | 95.8M |
| Profitability Metrics | |||||
| EBITDA | 2.8B | 2.6B | 2.7B | 2.3B | 2.1B |
| D&A | 697.5M | 715.3M | 723.9M | 745.4M | 732.6M |
| EBIT | 2.1B | 1.9B | 2.0B | 1.6B | 1.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026